Enoxaparin Increases D6 Receptor Expression and Restores Cytoskeleton Organization in Trophoblast Cells from Preeclampsia

Abstract

D6 is a scavenger receptor for CC chemokines expressed in the human placenta. It prevents excessive leukocyte tissue infiltration by internalizing chemokines through cytoskeleton-dependent intracellular transport. In preeclampsia (PE), the D6 receptor is overexpressed in trophoblast cells, but functionally impaired, due to cytoskeleton destructuring. Low molecular weight heparin (LMWH) represents a potential treatment for PE based on its anti-thrombotic and anti-inflammatory properties. Here, we investigated the effect of enoxaparin on D6 expression, and cytoskeleton organization primary cytotrophoblast cell cultures were obtained from the placentae of women with PE (n = 9) or uncomplicated pregnancy (n = 9). We demonstrated that enoxaparin is able to (i) increase D6 expression, and (ii) improve cytoskeletal fiber alignment in trophoblast cells from PE patients.

Mechanism of Chemotactic Cytokine Binding Protein D6 on Tumorigenicity and Metastasis of Breast Cancer Cells

“…As for its expression in other tissues or tumors and its biological function in tumors, it has not been reported [11] . D6 is a typical G protein-coupled receptor, which can bind almost all inflammatory CC (C-C Motif Chemokine Ligand (CCL) 2-5, 7, 8, 11-14, and 22, and has a weak binding ability to CCL-17, but does not bind to homeostatic and other CC [12] . D6 molecules recognize inflammatory CC specifically and bind only those with biological activity, but not those with any biological function such as CCL22.…”